Association of Serum Neuron-Specific Enolase and C-Reactive Protein With Disease Location and Endoscopic Inflammation Degree in Patients With Crohn's Disease

Objective: The objective of this study was to explore the association between serum markers neuron-specific enolase (NSE) and C-reactive protein (CRP) with intestinal lesion location and degree of inflammation in patients with Crohn's disease (CD).Design: The levels of serum NSE, CRP, and fecal calprotectin (FC) in patients with CD were analyzed retrospectively. The severity of inflammatory lesions in the intestinal wall was accessed using the Simple Endoscopic Score for Crohn's disease (SES-CD).Results: The levels of NSE in patients with CD were higher than those of healthy individuals (14.87 vs. 12.68 ng/ml, P < 0.001). The levels of CRP in patients with CD were higher than those of healthy individuals (12.30 vs. 3.40 mg/l, P < 0.001). The FC levels in patients with CD were higher than those of patients with non-inflammatory bowel disease (1,143.90 vs. 114.21 μg/g, P < 0.05). The levels of NSE in CD with ileal lesions and simultaneous ileal and colon lesions were significantly higher than those in patients with CD with colonic lesions. However, the CRP was higher in patients with colonic lesions than those with ileal lesions. The levels of NSE in patients with severe inflammation were higher than those in patients with moderate inflammation (15.95 vs. 13.89 ng/ml, P < 0.05). Similarly, the NSE levels in patients with CD with severe inflammation were higher than those in patients with CD with mild inflammation (15.95 vs. 13.53 ng/mL, P < 0.05). The levels of CRP in severe inflammation were higher than those in moderate inflammation (29.80 vs. 19.60 mg/l, P < 0.05). In addition, the CRP levels in severe inflammation were higher than those in mild inflammation (29.80 vs. 5.86 mg/l, P < 0.05). ROC curve analysis showed that when NSE was combined with CRP for distinguishing between patients with CD and those without CD, sensitivity increased to 80.41%, specificity increased to 74.66%, and a highest AUC was equal to 0.843.Conclusion: Our study shows that serum NSE and CRP can be used to assess the severity of CD as well as the location of intestinal involvement. Therefore, NSE and CRP could be used as the non-invasive tests in detecting the location and severity of disease in patients with CD in daily routine practice.

Download Full-text

Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease

Gastroenterología y Hepatología (English Edition) ◽

10.1016/j.gastre.2020.04.010 ◽

2021 ◽

Vol 44 (2) ◽

pp. 87-95

Author(s):

Francisco Guilherme Cancela Penna ◽

Rodrigo Macedo Rosa ◽

Fernando H. Pereira ◽

Pedro Ferrari Sales Cunha ◽

Stella Cristina S. Sousa ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Therapeutic Target ◽

Fecal Calprotectin ◽

C Reactive Protein ◽

Reactive Protein ◽

Combined Evaluation

Download Full-text

Correlation between levels of C-reactive protein and clinical activity in Crohn's disease

Digestive and Liver Disease ◽

10.1016/j.dld.2007.06.015 ◽

2007 ◽

Vol 39 (11) ◽

pp. 1006-1010 ◽

Cited By ~ 29

Author(s):

S. Karoui ◽

S. Ouerdiane ◽

M. Serghini ◽

T. Jomni ◽

L. Kallel ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Clinical Activity ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

Su1332 Long-Term Outcome of Patients With Crohn's Disease in Deep Remission: C-Reactive Protein Normalization Predicting Better Outcomes

Gastroenterology ◽

10.1016/s0016-5085(15)31603-6 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-477

Author(s):

Yun Qiu ◽

Ren Mao ◽

Yao He ◽

Bai-li Chen ◽

Zhi-rong Zeng ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

C Reactive Protein ◽

Term Outcome ◽

Long Term Outcome ◽

Reactive Protein

Download Full-text

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

Current Medical Research and Opinion ◽

10.1185/03007995.2013.779575 ◽

2013 ◽

Vol 29 (5) ◽

pp. 483-493 ◽

Cited By ~ 15

Author(s):

W. J. Sandborn ◽

J.-F. Colombel ◽

G. D’Haens ◽

S. E. Plevy ◽

J. Panés ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Maintenance Therapy ◽

Tumor Necrosis ◽

C Reactive Protein ◽

Reactive Protein ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

P673 Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjy222.797 ◽

2019 ◽

Vol 13 (Supplement_1) ◽

pp. S455-S456

Author(s):

H Shiga ◽

I Abe ◽

M Onodera ◽

R Moroi ◽

M Kuroha ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tight Control ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

P573. Assessment of serum C-reactive protein, faecal lactoferrin, and faecal calprotectin in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 Ustekinumab induction studies

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjw019.692 ◽

2016 ◽

Vol 10 (suppl 1) ◽

pp. S390.2-S391

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

C Reactive Protein ◽

Faecal Calprotectin ◽

Reactive Protein

Download Full-text

Plasma Arachidonic Acid-Rich Phospholipids in Crohn's Disease: Response to Treatment

Clinical Science ◽

10.1042/cs0910509 ◽

1996 ◽

Vol 91 (4) ◽

pp. 509-512 ◽

Cited By ~ 11

Author(s):

Stephen P. Pereira ◽

Theresa B. Cassell ◽

Jeffrey L Engelman ◽

Gordon E. Sladen ◽

Gerard M. Murphy ◽

...

Keyword(s):

Fatty Acids ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Polyunsaturated Fatty Acids ◽

Erythrocyte Sedimentation Rate ◽

Sedimentation Rate ◽

C Reactive Protein ◽

Reactive Protein ◽

Erythrocyte Sedimentation ◽

Polyunsaturated Phosphatidylcholine

1. Increased concentrations of plasma polyunsaturated fatty acids have been implicated in the pathogenesis of Crohn's disease. However, it is not known whether there are corresponding changes in circulating phospholipids - the major source of fatty acids in the plasma. 2. Fasting plasma samples were obtained from 17 control subjects and 13 patients with active Crohn's disease [Simple Index of Crohn's Disease Activity (SICDA) >6] before, and 2 and 8 weeks after, treatment with either a peptide diet or oral prednisolone. 3. Before treatment, the Crohn's disease patients had mildly active disease (SICDA 9.9 ± 0.8, erythrocyte sedimentation rate 26.4 ± 6.5 mm/h, serum C-reactive protein 2.8 ± 0.4 mg/l). The proportions of the polyunsaturated phosphatidylcholine species, 16:0–20:4 (10.0 ± 0.7%) and 16:0–22:6 (7.1 ± 0.8%), were both significantly higher than those in healthy controls (7.6 ± 0.5%, P < 0.01 and 5.3 ± 0.5%, P < 0.05 respectively). 4. After 2 weeks treatment, the SICDA in the Crohn's disease patients decreased to 3.2 ± 0.6 (P < 0.0001 compared with the pretreatment value), and there were corresponding falls in the erythrocyte sedimentation rate (to 12.6 ± 2.7 mm/h, P < 0.05) and C-reactive protein concentration (to 1.7 ± 0.3 mg/l, P < 0.05)—these improvements being maintained at 8 weeks. There was also a fall to normal values in 16:0–20:4 (to 7.7 ± 0.6%, P < 0.01 compared with the pretreatment value) and in 16:0–22:6 (to 5.7 ± 0.5%, P not significant), by week 8. 5. The proportions of polyunsaturated phosphatidylcholine molecular species were increased in the plasma of patients with active Crohn's disease, but fell to normal levels during disease remission. These observations are consistent with the theory that, in active Crohn's disease, the mucosal phospholipids containing polyunsaturated fatty acids are increased, contribute to eicosanoid synthesis and ‘spill’ into the plasma.

Download Full-text